litlas
ログインアカウント作成

Mark F. Brady

1983–2024 年に発表

54
論文数
19,375
被引用数
49
h 指数
53
i10 指数

被引用数

Mark F. Brady の年別被引用数1977 年: 被引用 1 件1985 年: 被引用 6 件1986 年: 被引用 1 件1987 年: 被引用 2 件1988 年: 被引用 2 件1989 年: 被引用 4 件1991 年: 被引用 1 件1992 年: 被引用 3 件1993 年: 被引用 7 件1994 年: 被引用 2 件1995 年: 被引用 4 件1996 年: 被引用 15 件1997 年: 被引用 29 件1998 年: 被引用 30 件1999 年: 被引用 37 件2000 年: 被引用 57 件2001 年: 被引用 51 件2002 年: 被引用 61 件2003 年: 被引用 65 件2004 年: 被引用 77 件2005 年: 被引用 62 件2006 年: 被引用 91 件2007 年: 被引用 103 件2008 年: 被引用 69 件2009 年: 被引用 110 件2010 年: 被引用 108 件2011 年: 被引用 125 件2012 年: 被引用 142 件2013 年: 被引用 103 件2014 年: 被引用 130 件2015 年: 被引用 97 件2016 年: 被引用 119 件2017 年: 被引用 158 件2018 年: 被引用 111 件2019 年: 被引用 573 件2020 年: 被引用 599 件2021 年: 被引用 544 件2022 年: 被引用 407 件2023 年: 被引用 288 件2024 年: 被引用 405 件2025 年: 被引用 214 件2026 年: 被引用 2 件1978〜1984 年は被引用が無いため表示していません1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,625 件、この内訳の 25.7%イギリス: 引用元論文 466 件、この内訳の 7.4%中国: 引用元論文 454 件、この内訳の 7.2%イタリア: 引用元論文 385 件、この内訳の 6.1%カナダ: 引用元論文 298 件、この内訳の 4.7%フランス: 引用元論文 269 件、この内訳の 4.2%ドイツ: 引用元論文 263 件、この内訳の 4.2%日本: 引用元論文 248 件、この内訳の 3.9%スペイン: 引用元論文 225 件、この内訳の 3.6%オーストラリア: 引用元論文 184 件、この内訳の 2.9%オランダ: 引用元論文 164 件、この内訳の 2.6%韓国: 引用元論文 150 件、この内訳の 2.4%
0%25.7%その他 25.1%

機関

分野

  • Medicine76%
  • Biochemistry, Genetics and Molecular Biology17%
  • Immunology and Microbiology2.9%
  • Materials Science1%
  • Mathematics0.5%
  • Dentistry0.5%
  • その他2.1%

トピック

  • Ovarian cancer diagnosis and treatment16.5%
  • PARP inhibition in cancer therapy8.9%
  • Endometrial and Cervical Cancer Treatments7.2%
  • Intraperitoneal and Appendiceal Malignancies4.1%
  • BRCA gene mutations in cancer2.8%
  • DNA Repair Mechanisms1.9%
  • その他58.6%

共著者

全論文

検索で開く
  1. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

    著者: Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang - New England Journal of Medicine 2011 被引用: 2,384

  2. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

    著者: Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Philip J. DiSaia, Larry J. Copeland, William T. Creasman, Frederick B. Stehman, Mark F. Brady, Robert A. Burger, J.T. Thigpen, Michael J. Birrer, Steven Waggoner, David H. Moore, Katherine Y. Look, Wui-Jin Koh, Bradley J. Monk - The Lancet 2017 被引用: 679

  3. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    著者: Robert L. Coleman, Gini F. Fleming, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Michael Friedländer, Aikou Okamoto, Kathleen N. Moore, Noa Ben-Baruch, Theresa L. Werner, Noelle Cloven, Ana Oaknin, Paul DiSilvestro, Mark A. Morgan, Joo‐Hyun Nam, Charles A. Leath, Shibani Nicum, Andrea R. Hagemann, Ramey D. Littell, David Cella, Sally Baron‐Hay, Jesús García-Donás, Mika Mizuno, Katherine M. Bell‐McGuinn, Danielle Sullivan, Bruce Allen Bach, Sudipta Bhattacharya, Christine K. Ratajczak, Peter Ansell, Minh H. Dinh, Carol Aghajanian, Michael A. Bookman - New England Journal of Medicine 2019 被引用: 929

  4. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    著者: Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel - The Lancet Oncology 2017 被引用: 602

  5. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

    著者: Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Huang, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Chenglin Ye, Carlos Bais, Leslie M. Randall, John K. Chan, J. Stuart Ferriss, Robert L. Coleman, Carol Aghajanian, Thomas J. Herzog, Philip J. DiSaia, Larry J. Copeland, Robert S. Mannel, Michael J. Birrer, Bradley J. Monk - Journal of Clinical Oncology 2019 被引用: 483

  6. Inherited Mutations in Women With Ovarian Carcinoma

    著者: Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer - JAMA Oncology 2015 被引用: 764

  7. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

    著者: Robert L. Coleman, Nick M. Spirtos, Danielle Enserro, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Jae‐Weon Kim, Sang‐Yoon Park, Byoung‐Gie Kim, Joo-Hyun Nam, Keiichi Fujiwara, Joan L. Walker, A.Catherine Casey, Angeles Alvarez Secord, Steve Rubin, John K. Chan, Paul DiSilvestro, Susan A. Davidson, David E. Cohn, Krishnansu S. Tewari, Karen Basen‐Engquist, Helen Huang, Mark F. Brady, Robert S. Mannel - New England Journal of Medicine 2019 被引用: 334

  8. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

    著者: Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, David Cella, William P. Tew, Noelle G. Cloven, Carolyn Y. Muller, David P. Bender, Richard G. Moore, David P. Michelin, Steven E. Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman - Journal of Clinical Oncology 2022 被引用: 87

  9. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

    著者: William P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge, Katherine Y. Look, Daniel L. Clarke‐Pearson, Martin Davidson - New England Journal of Medicine 1996 被引用: 2,872

  10. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

    著者: John K. Chan, Mark F. Brady, Richard T. Penson, Helen Huang, Michael J. Birrer, Joan L. Walker, Paul DiSilvestro, Stephen C. Rubin, Lainie P. Martin, Susan A. Davidson, Warner K. Huh, David M. O’Malley, Matthew Boente, Helen Michael, Bradley J. Monk - New England Journal of Medicine 2016 被引用: 367

  11. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

    著者: Bradley J. Monk, Mark F. Brady, Carol Aghajanian, Heather A. Lankes, Tina Rizack, Joseph W. Leach, J.M. Fowler, Robert V. Higgins, P. Hanjani, Mark A. Morgan, Robert P. Edwards, William H. Bradley, Tatjana Kolevska, Periklis Foukas, E. Swisher, Karen S. Anderson, Raphaël Gottardo, J.K. Bryan, Mona Newkirk, Kristi L. Manjarrez, Robert S. Mannel, Robert M. Hershberg, George Coukos - Annals of Oncology 2017 被引用: 93

  12. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

    著者: Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Robert A. Burger, Krishnansu S. Tewari, Floor Backes, Robert S. Mannel, Gretchen Glaser, Cheryl L. Bailey, Stephen C. Rubin, John T. Soper, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Michael J. Birrer, Elizabeth M. Swisher - Clinical Cancer Research 2017 被引用: 235

  13. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

    著者: Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter Harper, David S. Alberts, Michael Friedländer, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, Chrisann Accario-Winslow, Lawrence M. Roth - Journal of Clinical Oncology 2009 被引用: 707

  14. Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

    著者: Helen Mackay, Mark F. Brady, Amit M. Oza, Alexander Reuß, Éric Pujade-Lauraine, Ann Marie Swart, Nadeem Siddiqui, Nicoletta Colombo, Michael A. Bookman, Jacobus Pfisterer, Andreas du Bois - International Journal of Gynecological Cancer 2010 被引用: 271

  15. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

    著者: Joan L. Walker, Mark F. Brady, Lari Wenzel, Gini F. Fleming, Helen Huang, Paul DiSilvestro, Keiichi Fujiwara, David S. Alberts, Wenxin Zheng, Krishnansu S. Tewari, David E. Cohn, Matthew A. Powell, Linda Van Le, Susan A. Davidson, Heidi J. Gray, Peter G. Rose, Carol Aghajanian, Tashanna Myers, Angeles Alvarez Secord, Stephen C. Rubin, Robert S. Mannel - Journal of Clinical Oncology 2019 被引用: 232

  16. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

    著者: Carlos Bais, Barbara M. Mueller, Mark F. Brady, Robert S. Mannel, Robert A. Burger, Wei Wei, Koen M. Marien, Mark Kockx, Amreen Husain, Michael J. Birrer, NRG Oncology/Gynecologic Oncology Group - JNCI Journal of the National Cancer Institute 2017 被引用: 108

  17. Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group

    著者: J.T. Thigpen, Mark F. Brady, Ronald D. Alvarez, Mark Adelson, Howard D. Homesley, Alberto Manetta, John T. Soper, Fred T. Given - Journal of Clinical Oncology 1999 被引用: 483

  18. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study

    著者: Jeffrey G. Bell, Mark F. Brady, Robert C. Young, Janice M. Lage, Joan L. Walker, Katherine Y. Look, G. Scott Rose, Nick M. Spirtos - Gynecologic Oncology 2006 被引用: 308

  19. Clinical Trials in Recurrent Ovarian Cancer

    著者: Michael Friedländer, Edward L. Trimble, Anna V. Tinker, David S. Alberts, Elisabeth Åvall‐Lundqvist, Mark F. Brady, Philipp Harter, Sandro Pignata, Eric Pujade Lauraine, Jalid Sehouli, Ignace Vergote, Philip Beale, Rudd Bekkers, Paula Calvert, Lawrence Copeland, Rosalind Glasspool, Antonio González-Martı́n, Dionysis Katsaros, Jae‐Weon Kim, Brigitte Miller, Diane Provencher, Larry Rubinstein, Mostafa Atri, Alain G. Zeimet, Monica Bacon, Henry C Kitchener, Gavin Stuart - International Journal of Gynecological Cancer 2011 被引用: 231

  20. Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

    著者: Francis J. Major, John A. Blessing, Steven G. Silverberg, C. Paul Morrow, William T. Creasman, John L. Currie, Edgardo Yordan, Mark F. Brady - Cancer 1993 被引用: 665

  21. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study

    著者: Helen Huang, Mark F. Brady, David Cella, Gini F. Fleming - International Journal of Gynecological Cancer 2007 被引用: 214

  22. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

    著者: Jung‐Min Lee, Mark F. Brady, Austin Miller, Richard G. Moore, Helen Mackay, Leah McNally, Jayanthi Lea, Daron Street, Stéphanie Lheureux, Megan McDonald, Linda Duska, Guilherme Cantuaria, Juraj Kavecansky, Charles A. Leath, Matthew A. Powell, Mark G. Cadungog, Peter G. Rose, Yong‐Man Kim, Helen Huang, Michèle Provencher, Lari Wenzel, Michael A. Bookman, Elise C. Kohn, Angeles Alvarez Secord - Journal of Clinical Oncology 2024 被引用: 22

  23. Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

    著者: Tate Thigpen, Mark F. Brady, Howard D. Homesley, John T. Soper, Jeffrey G. Bell - Journal of Clinical Oncology 2001 被引用: 190

  24. Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    著者: J.T. Thigpen, Mark F. Brady, Howard D. Homesley, John H. Malfetano, Brent DuBeshter, Robert A. Burger, Shu Liao - Journal of Clinical Oncology 2004 被引用: 392